Aytu BioPharma Rebounds as Depression Drug Prescriptions Surpass Expectations

Englewood, Tuesday, 22 September 2026.
Aytu BioPharma reported a 6.4% fourth-quarter revenue increase to $16.1 million, fueled by its depression treatment EXXUA, which saw total quarterly prescriptions skyrocket by 138%.